On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > REGULATORY
REGULATORY
- HIV Meds Dovato, Pifeltro to Join NHI Price List on January 22
January 16, 2020
- Australia to Provide Expedited Reviews for OTC and Quasi-Drugs Approved in Japan
January 16, 2020
- Rotavirus Vaccine to Be Included in Public Vaccination Programs Starting Oct. 1
January 16, 2020
- Novartis’ Eylea Contender Up for MHLW Panel Review on January 27
January 15, 2020
- Japan Approves 2 HIV Drugs, Listing Expected Soon
January 15, 2020
- Japan Likely to Take Pass on Rewarding Formulary Initiatives under Medical Fee Schedule
January 14, 2020
- Osaka Univ. Professor, Mitsubishi Tanabe Receive Prime Minister’s R&D Award for Contributions to Development of SGLT2 Inhibitor
January 14, 2020
- MHLW to Beef Up GMP Inspections at API Manufacturing Sites in Asia from FY2020 in Response to Series of Supply Disruptions
January 6, 2020
- MHLW Revises Safety Guidance on FIH Studies Following Death of Subject
January 6, 2020
- MHLW to Set Up New Study Group on Detailing Activities Report System for All Medical Institutions
January 6, 2020
- JETRO’s New York Office Gets First Health and Welfare Head in 2 Years
January 1, 2020
- Councilor Mori Urges Drug Maker Management to Straighten Up as He Bids Farewell to MHLW
December 27, 2019
- Health Ministry Panel Calls for Simplified Certification Process for Vaccines to Ensure Stable Supplies
December 27, 2019
- Japan Lays Out Action Plan for Whole Genome Analysis; Preliminary Project to Cover 64,000 Cancer Patients, 28,000 for Intractable Diseases
December 27, 2019
- AMED’s Kono Tapped to Lead Medical Device Review at MHLW
December 26, 2019
- Japan's Global Health Confab to Prepare New Grand Design for Regulatory Harmonization in Asia
December 26, 2019
- MHLW to Establish Clinical Research Centers for Pediatric, Rare Diseases: FY2020 Budget
December 25, 2019
- 930 Million Yen Allocated for Amended PMD Law-Related Projects: MHLW Pharma Safety Bureau
December 24, 2019
- Fumi Yamamoto 1st Woman to Become MHLW’s Top Pharmacy Officer
December 23, 2019
- Govt’s All-Generation Social Security Panel Compiles Interim Report, No Mention of OTC-Like Drugs
December 23, 2019
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…